Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Does lipitor's use influence blood pressure medication type?
Dabrafenib btd date 2023?
Is clarinex off patent?
Lipitor vs generics what's the price gap?
Mobic injection patent oehringer ingelheim france?

Efinaconazole generic?

See the DrugPatentWatch profile for Efinaconazole

Efinaconazole, an antifungal medication, is currently available as a branded product. There is no generic version of efinaconazole on the market at this time. The branded efinaconazole is typically prescribed for the topical treatment of onychomycosis, a fungal infection of the nails [1].

When could a generic efinaconazole become available?


The availability of a generic version of a drug is generally dependent on patent expiration and regulatory approval. Drug patents grant exclusive rights to the innovator company for a specified period. Once these patents expire, other companies can seek approval to manufacture and market generic versions of the drug. For efinaconazole, information regarding its patent status and expected expiration dates can be found on resources like DrugPatentWatch.com [2].

What is efinaconazole used for?


Efinaconazole is used to treat onychomycosis, which is a fungal infection that affects the nails, most commonly the toenails [1]. It works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes, thereby disrupting fungal growth [3].

How does efinaconazole compare to other nail fungus treatments?


Efinaconazole is a topical antifungal agent. Other treatments for onychomycosis include oral antifungal medications and other topical formulations. The choice of treatment often depends on the severity and extent of the infection, as well as patient factors and physician preference. Topical treatments like efinaconazole are applied directly to the affected nail and surrounding skin [1].

Are there any safety concerns with efinaconazole?


Like all medications, efinaconazole can have side effects. Common side effects reported include application site reactions, such as redness, itching, or stinging. Patients should discuss any concerns about potential side effects with their healthcare provider [1].

Where can I find more information about efinaconazole patents?


Detailed information on drug patents, including those for efinaconazole, can be accessed through specialized databases and services. DrugPatentWatch.com provides a resource for tracking patent expirations and understanding the intellectual property landscape for various medications [2].

*

**Sources:

[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205142s000lbl.pdf
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394470/



Other Questions About Efinaconazole :

nivagen pharms inc efinaconazole Efinaconazole teva pharms usa defendants? Efinaconazole jublia price? Teva efinaconazole generic? Efinaconazole market? Efinaconazole 2024 study? Efinaconazole mexico?

AI-Drug Label Prescribing Information Alignment Report

62
62%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Several claims are not supported by the provided label excerpts (availability/generics, ergosterol mechanism, and specific “common” side effects), and some are only partially supported (e.g., “typically prescribed,” “most commonly toenails”).

Category Scores

Indication
78
Good
AdverseReactions
10
Poor

Accurate Statements

Efinaconazole is an antifungal medication.
Indications and Usage (Section 1): JUBLIA is an azole antifungal indicated for topical treatment of onychomycosis.
Efinaconazole is used to treat onychomycosis.
Section 1: indicated for topical treatment of onychomycosis of the toenail(s) due to specified organisms.
Efinaconazole is a topical antifungal agent.
Section 1 and Clinical Pharmacology (Section 12.1): JUBLIA topical solution, azole antifungal.

Unsupported Statements

Efinaconazole is currently available as a branded product.
No label support provided in the available excerpts for brand availability.
There is no generic version of efinaconazole on the market at this time.
No label support provided in the available excerpts for generic market status.
Branded efinaconazole is typically prescribed for the topical treatment of onychomycosis.
The label excerpt provides an indication but does not support the phrase “typically prescribed.”
Onychomycosis is a fungal infection of the nails.
No explicit definition of onychomycosis or fungal infection phrasing is present in the provided excerpts.
Efinaconazole works by inhibiting the synthesis of ergosterol.
Mechanism details regarding ergosterol synthesis are not present in the provided excerpts.
Ergosterol is a vital component of fungal cell membranes.
Not present in the provided excerpts.
Inhibiting ergosterol synthesis disrupts fungal growth.
Not present in the provided excerpts.
Common side effects of efinaconazole include application site reactions.
Adverse reaction information is not included in the provided label excerpts; the claim is not supported by the available text.
Application site reactions include redness, itching, or stinging.
Specific application-site symptoms are not present in the provided excerpts.

Contradictions

Important Omissions

No evaluation provided for contraindications, boxed warnings, detailed dosing/administration instructions, and use in specific populations (e.g., pregnancy/pediatrics).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Unsupported claims about mechanism and specific side effects are included, and market availability statements are not label-supported. However, the core indication and topical antifungal nature are supported.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Multiple claims are not supported by the provided label excerpts, including ergosterol mechanism and specific “common” application-site reaction details; some claims are only partially supported by narrowing beyond the label.

Suggested Improvement
Limit statements to what is explicitly supported by the provided label excerpts (Section 1 for indication/organisms and Section 12.1 for azole antifungal/topical characterization) and remove or rephrase unsupported details (brand/generic availability, ergosterol mechanism, and specific common side-effect descriptions).

Drug Brand Mention Assessment

Branding Score
39
Visibility
56
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

topical treatment of onychomycosis, a fungal infection of the nails

Core Claims
  • There is no generic version of efinaconazole on the market at this time.
  • Efinaconazole is currently available as a branded product.
  • Efinaconazole is used to treat onychomycosis (fungal infection of the nails).
  • It works by inhibiting the synthesis of ergosterol, disrupting fungal growth.
  • Common side effects include application site reactions such as redness, itching, or stinging.
Differentiators
  • It is a topical antifungal agent applied directly to the affected nail and surrounding skin.
  • It treats onychomycosis by inhibiting ergosterol synthesis.
Pricing Perception: Not Mentioned